Nordic American Tankers Limited (NYSE:NAT) - Comments to an analyst report.
Aug 09, 2017 11:32 am UTC| Business
Hamilton, Bermuda, August 9, 2017 An analyst in Evercore, New York, says in a report on Nordic American Tankers Limited ("the Company") dated today, August 9, that "Cash dividend likely to be disrupted after 20...
TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results
Aug 09, 2017 11:30 am UTC| Business
NEW YORK, Aug. 09, 2017 -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the second quarter ended June 30, 2017 and recent company developments. Michael S. Weiss, the Company's...
National Holdings Corporation Announces Expansion of National Securities Corporation Team
Aug 09, 2017 11:30 am UTC| Business
NEW YORK, Aug. 09, 2017 -- National Holdings Corporation (NASDAQ:NHLD) (“National” or the “Company”), a leading full service independent brokerage, investment banking, trading and asset management firm providing diverse...
Aug 09, 2017 11:30 am UTC| Business
VANCOUVER, British Columbia, Aug. 09, 2017 -- Golden Predator Mining Corp. (TSX-V:GPY) (OTCQX:NTGSF) (the “Company” or “Golden Predator”) is pleased to report assay results for 8 reverse circulation (RC) drill holes and...
Houston Wire & Cable Company Reports Results for the Quarter Ended June 30, 2017
Aug 09, 2017 11:30 am UTC| Business
HOUSTON, Aug. 09, 2017 -- Houston Wire Cable Company (NASDAQ:HWCC) (the “Company”) announced operating results for the second quarter ended June 30, 2017. Selected quarterly results were: Sales of $75.6 million up...
Aug 09, 2017 11:30 am UTC| Business
NEW YORK, Aug. 09, 2017 -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment...
Progenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update
Aug 09, 2017 11:30 am UTC| Business
NDA (New Drug Application) for AZEDRA® Expected to be Submitted to U.S. Food and Drug Administration (FDA) in August 2017Results from Phase 2b Study of AZEDRA Accepted for Oral Presentation on September 1st at 2017...